Srilaxmi Kalavalapalli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Srilaxmi Kalavalapalli has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Bril
Division of Endocrinology, Diabetes and Metabolism University of Alabama at Birmingham Birmingham Alabama USA
2 shared publications - Kenneth Cusi
Division of Endocrinology, Diabetes and Metabolism The University of Florida Gainesville Florida USA
2 shared publications - Andrea Ortiz Rocha
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville , FL 32610
1 shared publication - Anu Sharma
College of Medicine, University of Florida, Gainesville, USA
1 shared publication - Diana Barb
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville , FL 32610
1 shared publication - Eddison Godinez Leiva
Division of Endocrinology, Diabetes and Metabolism, University of Florida College of Medicine, Gainesville, USA
1 shared publication
Latest Publications
- 20 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (9) , 2620-2629
Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption
Objective: This study compared in vivo changes in hepatic phosphate metabolites using phosphorus magnetic resonance spectroscopy (31P-MRS) in patients with vs without metabolic dysfunction-associated steatotic liver disease (MASLD) after oral fructose consumption. Methods: Thirty-seven overweight or obese patients without diabetes underwent a 2-hour oral glucose tolerance test, a fasting liver proton magnetic resonance spectroscopy, and a 31P-MRS before and during 60 minutes after an oral 75-gram fructose challenge. Results: Before fructose consumption, there were no differences in ATP, phosphomonoesters (PME), or phosphodiesters between groups. After fructose, patients without MASLD had a rapid increase in PME (from 15.5 ± 4.8 to 19.3 ± 5.1 within 15 minutes, P = .033). In these patients, inorganic phosphate (Pi) decreased during the first 30 minutes but then increased, leading to higher than baseline levels (from 10.2 ± 1.9 to 11.8 ± 2.8, P = .037). ATP significantly dropped in patients without MASLD within 15 minutes (from 21.8 ± 3.4 to 19.9 ± 4.0, P = .018), with persistently lower levels after 60 minutes (19.1 ± 4.1, P = .006 vs baseline). However, all these responses to oral fructose appeared blunted in patients with MASLD, with unchanged PME levels and only showing an Pi increase 45 minutes after fructose consumption. ATP levels showed a nonsignificant drop in the first 15 minutes with recovery of baseline levels at minute 30. Conclusion: Following fructose consumption, patients with MASLD exhibited distinct patterns of change in phosphate metabolites, reflecting differences in hepatic metabolic responses. These findings suggest altered hepatic metabolic handling of fructose in MASLD, which may have implications for disease progression.
- 20 March 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (9) , 2620-2629
Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption
Objective: This study compared in vivo changes in hepatic phosphate metabolites using phosphorus magnetic resonance spectroscopy (31P-MRS) in patients with vs without metabolic dysfunction-associated steatotic liver disease (MASLD) after oral fructose consumption. Methods: Thirty-seven overweight or obese patients without diabetes underwent a 2-hour oral glucose tolerance test, a fasting liver proton magnetic resonance spectroscopy, and a 31P-MRS before and during 60 minutes after an oral 75-gram fructose challenge. Results: Before fructose consumption, there were no differences in ATP, phosphomonoesters (PME), or phosphodiesters between groups. After fructose, patients without MASLD had a rapid increase in PME (from 15.5 ± 4.8 to 19.3 ± 5.1 within 15 minutes, P = .033). In these patients, inorganic phosphate (Pi) decreased during the first 30 minutes but then increased, leading to higher than baseline levels (from 10.2 ± 1.9 to 11.8 ± 2.8, P = .037). ATP significantly dropped in patients without MASLD within 15 minutes (from 21.8 ± 3.4 to 19.9 ± 4.0, P = .018), with persistently lower levels after 60 minutes (19.1 ± 4.1, P = .006 vs baseline). However, all these responses to oral fructose appeared blunted in patients with MASLD, with unchanged PME levels and only showing an Pi increase 45 minutes after fructose consumption. ATP levels showed a nonsignificant drop in the first 15 minutes with recovery of baseline levels at minute 30. Conclusion: Following fructose consumption, patients with MASLD exhibited distinct patterns of change in phosphate metabolites, reflecting differences in hepatic metabolic responses. These findings suggest altered hepatic metabolic handling of fructose in MASLD, which may have implications for disease progression.
- Open Access
- 11 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , e1813-e1822
Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.
- 11 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (7) , e1813-e1822
Open AccessSeverity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.